Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-1117570 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NBI-1117570: Lower-dose | EXPERIMENTAL | Participants will receive a lower-dose of NBI-1117570. |
| NBI-1117570: Higher-dose | EXPERIMENTAL | Participants will receive a higher-dose of NBI-1117570. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NBI-1117570. |
| Name | Type | Description |
|---|---|---|
| NBI-1117570 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * 18 to 55 years of age * Primary diagnosis of schizophrenia ≥1 year before screening. * Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization. * Participant must have ha...
NBI-1117570 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in inpatient adults with schizophrenia to assess its safety and efficacy.
NBI-1117570 targets muscarinic receptors, which are a class of receptors involved in various neurological and psychiatric functions. By acting on these receptors, the drug aims to modulate signaling pathways relevant to schizophrenia. This mechanism is being investigated in clinical trials for its potential therapeutic effects.
NBI-1117570 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NBIX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with schizophrenia.
NBI-1117570 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is designed to assess the drug's efficacy and safety in adults with schizophrenia.
NBI-1117570 is being studied in a Phase 2 clinical trial with the identifier NCT07288333, titled "Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia." This randomized, double-blind, placebo-controlled trial is recruiting participants in Bulgaria, Romania, and the United Kingdom, with an enrollment target of 120 adults aged 18 years and older.
NBI-1117570 is a unique investigational compound and is not known to be the same as any other marketed drug. It is being developed specifically by Neurocrine Biosciences for schizophrenia and is currently in Phase 2 trials. No alternative names have been associated with this drug in the available information.